Amgen Inc - Company Profile
Powered by 
All the data and insights you need on Amgen Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Amgen Inc Strategy Report
- Understand Amgen Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View moreAmgen Inc (Amgen) is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines in therapeutic areas of cardiovascular, oncology/hematology, inflammation, bone health, neurological disorders and nephrology. The company develops products using advanced human genetics to analyze the difficulties of disease and understand the fundamentals of human biology. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels and through partnerships with other companies. The company has presence in Asia Pacific, Europe, Middle East, North America and Australia. Amgen is headquartered in Thousand Oaks, California, the US.
Headquarters
United States of America
Address
One Amgen Center Drive, Thousand Oaks, California, 91320
Website
www.amgen.com
Telephone
1 805 4471000
No of Employees
26,700
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
AMGN (NASD)
Revenue (2022)
$28.2B
7.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
2.5%
(2022 vs 2021)
Market Cap*
$143.2B
Net Profit Margin (2022)
XYZ
-4.3%
(2022 vs 2021)
* As of and is in US$
Amgen Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | Aranesp |
| Innovative Human Therapeutics: | Enbrel |
| Oncology/Hematology | Epogen |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Corporate Changes/Expansions | In February, the company launched its manufacturing site in Central Ohio. |
| 2023 | Others | In December, the company received the US FDA priority review for its biologics license application for tarlatamab to treat advanced small-cell lung cancer. |
| 2023 | Contracts/Agreements | In November, the company announced a collaboration with PostEra to leverage PostEra's Proton and the company's drug discovery expertise to advance up to 5 small molecule programs. |
Competitor Comparison
| Key Parameters | Amgen Inc | F. Hoffmann-La Roche Ltd | Pfizer Inc | AbbVie Inc | Sanofi |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United States of America | United States of America | France |
| City | Thousand Oaks | Basel | New York | North Chicago | Paris |
| State/Province | California | - | New York | Illinois | Ile-de-France |
| No. of Employees | 26,700 | 103,605 | 88,000 | 50,000 | 87,994 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Robert A. Bradway | Chairman; Chief Executive Officer | Executive Board | 2012 | 60 |
| Peter H. Griffith | Executive Vice President; Chief Financial Officer | Senior Management | 2020 | 64 |
| Mike Zahigian | Chief Information Officer; Senior Vice President | Senior Management | - | - |
| David M. Reese, M.D | Chief Technology Officer; Executive Vice President | Senior Management | 2023 | - |
| Nancy A. Grygiel | Senior Vice President - Worldwide Compliance and Business Ethics; Chief Compliance Officer | Senior Management | 2020 | 55 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward